Baird lowered the firm’s price target on Biohaven (BHVN) to $52 from $57 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results where its incremental clinical progress was offset by OCD miss.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHVN:
- Biohaven Ltd.: Strategic Shift and Upcoming Milestones Justify Buy Rating Despite Setbacks
- Biohaven price target lowered to $30 from $54 at H.C. Wainwright
- 3 Best Stocks to Buy Now, 8/12/2025, According to Top Analysts
- Promising Developments and Regulatory Progress at Biohaven Ltd. Support Buy Rating
- Biohaven’s Strategic Advances and Promising Data Drive Buy Rating